

Clinical and Experimental RHEUMATOLOGY

An independent, international journal conveying the latest in the field of rheumatology


Editors: Stefano Bombardieri, MD (*Chief*) (Italy), Barbara M. Ansell, MD (*Pediatric Rheumatology section*) (UK),
Graham R.V. Hughes, MD (UK), Haralampos M. Moutsopoulos, MD (*Greece*), Paul E. Phillips, MD (USA)

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY provides a international forum for both clinicians and scientists wishing to keep up with the latest developments in the field of rheumatology. In addition to *Original Articles*, *Rapid Papers*, and *Case Reports*, every issue contains an *Editorial* and a *Review* designed to update readers on the hottest topics in this complex and rapidly growing field.

We were also the first in our field to introduce a regular section on **Pediatric Rheumatology**.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is not the official organ of any professional society and is proud of its editorial independence. Our international editorial board and outside referees provide a fair and careful screening of all articles submitted for publication.

Subscribe now and keep abreast of what's happening around the world in rheumatology! We are offering very special rates for professionals in training, and ACR and EULAR members.



CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

via S. Maria 31, 56126 Pisa, Italy tel: (50) 40124 Fax: (50) 553.444

- Please send me a complementary copy of the journal.
 Please enter my subscription for the calendar year 1993 (6 issues plus supplements).

	<u>Italy</u>	<u>Europe</u>	<u>Other</u>
<input type="checkbox"/> Individual	Lit. 85.000	\$115	\$115 / \$145*
<input type="checkbox"/> Institutional	Lit. 120.000	\$135	\$135 / \$165*
<input type="checkbox"/> In-training**	Lit. 45.000	\$45	\$45
<input type="checkbox"/> ACR and EULAR members	\$85.00		

Check enclosed (payable to *Clinical & Experimental Rheumatology*)

Please charge to my credit card account (*circle one*):

AMERICAN EXPRESS / DINERS / VISA / MASTERCARD / EUROCARD

Credit card no.

Expiration date

First name

Last name

Signature

Professional address:

Home address:

Advance payment is required. Payments from abroad must be by international cheque or credit card.

Rates include supplements and postage. Issues are sent overseas by surface mail (*The higher rate reflects the surcharge for air mail delivery).

Individual subscriptions must be in the name of and paid for by the individual. **Students, trainees and fellows must include a letter from their supervisor.

BMJ Publishing Group

Journals

BMJ

Published Weekly

Annals of the Rheumatic Diseases - *monthly*
Archives of Disease in Childhood - *monthly*
British Heart Journal - *monthly*
British Journal of Industrial Medicine - *monthly*
British Journal of Ophthalmology - *monthly*
Cardiovascular Research - *monthly*
Genitourinary Medicine - *bi-monthly*
Gut - *monthly*
Journal of Clinical Pathology - *monthly*
Journal of Epidemiology and Community Health - *bi-monthly*
Journal of Medical Ethics - *quarterly*
Journal of Medical Genetics - *monthly*
Journal of Neurology, Neurosurgery and Psychiatry - *monthly*
Quality in Health Care - *quarterly*
Thorax - *monthly*
Tobacco Control: An International Journal - *quarterly*

BMA News Review - *monthly*
British Dental Journal - *22 issues a year*
BDA News - *19 issues a year*
British Journal of Anaesthesia - *monthly*
Bulletin of Medical Ethics - *10 issues a year*
Current Work in the History of Medicine - *quarterly*
Eye - *bi-monthly*
Health Visitor - *monthly*
Medical History - *quarterly*
Medical History Supplement - *annually*


*For full details or a sample copy please contact:
Rachel Armitage, Journals Marketing, BMJ Publishing Group,
BMA House, Tavistock Square, London WC1H 9JR*

Is early joint damage acceptable in today's RA patient?

The majority of patients with Rheumatoid Arthritis will suffer erosive joint damage within 2 years of symptom onset offering a relatively narrow window of opportunity when disease modifying treatment can achieve most.¹

Today, our potential to suppress early joint damage in RA is highlighted by the results of a recent trial.² In this double-blind, randomised study in patients of median disease duration less than 9 months a significant slowing of joint damage was evident with Salazopyrin EN-tabs compared with hydroxychloroquine at 24 and 48 weeks.² Furthermore, the difference was still significant at 3-year follow-up.³ In the words of the authors, "the first blow is half the battle".³

Radiographic progression in patients treated with Salazopyrin EN-tabs or hydroxychloroquine.^{2,3}



When NSAIDs alone fail to preserve function and mobility

Salazopyrin[®] EN-tabs

enteric coated sulphasalazine

Today's choice to preserve tomorrow's lifestyle.

Abbreviated Prescribing Information

Presentation: Yellow enteric coated tablets, logo on one side, containing sulphasalazine 0.5g. Uses: Rheumatoid Arthritis unresponsive to NSAIDs. Dose: Do not break tablets. Adults/Elderly: 0.5g/day for a week, dose increasing by 0.5g/day weekly to a maximum of 3g/day in divided doses. Children: no recommendation. Contra-indications: Sulphonamide or salicylate sensitivity. Infants under 2 years of age. Precautions: Monthly blood checks and LFTs for 3 months. Care in hepatic, renal disease, porphyria or glucose-6-phosphate dehydrogenase deficiency. Adverse Effects: Nausea, headache, rash, loss of appetite, raised temperature. Rarely serious ADRs; Haematological: e.g. marrow depression, anaemias; Hypersensitivity: e.g. Stevens-Johnson syndrome, photosensitivity, lung complications, fever; G-I Reactions: e.g. hepatitis; CNS: e.g. neuropathy; Fertility: reversible oligospermia; Renal: e.g. proteinuria. Pregnancy and Lactation: No evidence for teratogenic or icteric hazards. Drug in breast milk should not be a risk to healthy infant. Package Quantities: 125 tablets in easy-open pack. Basic NHS Cost: EN-tabs 125 (UK price) £12.75. Legal Status: POM (Prescription Only Medicine). UK Product Licence Number: PL 0009/5007R. Product Authorisation Number (Ireland): PA107/5/2. Product Licence and Product Authorisation Holder: Pharmacia Biosystems Ltd, Davy Avenue, Knowlhill, Milton Keynes MK5 8PH. Distributed in UK by: Kabi Pharmacia Ltd, Davy Avenue, Knowlhill, Milton Keynes MK5 8PH. Tel: (0908) 661101. Distributed in Ireland by: Cahill May Roberts for Kabi Pharmacia (Ireland) Ltd, Chapelizod, Dublin 20.

References

1. Brook A, Corbett M. Annals of the Rheumatic Diseases 1977; 36: 71-73. 2. Van der Heijde DM, et al. Lancet 1989; i: 1036-1038. 3. Van der Heijde DM, et al. Lancet 1990; i: 539.